V212 (inactivated varicella-zoster virus vaccine) in Adult Patients with Solid Tumor or Hematologic Malignancies

What is the purpose of this trial?

This is a randomized, double-blind, placebo-controlled study to assess the safety and tolerability of V212 when administered to adults with solid tumor malignancy (STM) or hematologic malignancy (HM) and to determine whether V212 reduces the incidence of herpes zoster (HZ) in adults with STM or HM, as compared to placebo.

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Merck
Last Updated:
Study HIC#: 1205010258